QGEN
NYSEQiagen N.V.
Price$41.17-0.35 (-0.83%)
01:30 PM07:45 PM
News · 26 weeks33+100%
2026-01-182026-07-12
Mix1690d
- Dividends8(50%)
- Analyst4(25%)
- Earnings2(13%)
- Leadership1(6%)
- Other1(6%)
Latest news
25 items- PRQIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora OutbreakMore than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United
- PRQIAGEN N.V. to Release Results for Q2 2026 and Hold WebcastQIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 2545624 To avoid waiting time, please join the event co
- PRQIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in EuropeNew CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))
- ANALYSTQiagen downgraded by Berenberg with a new price targetBerenberg downgraded Qiagen from Buy to Hold and set a new price target of $45.50
- ANALYSTKepler initiated coverage on Qiagen with a new price targetKepler initiated coverage of Qiagen with a rating of Hold and set a new price target of $38.60
- ANALYSTQiagen upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Qiagen from Equal-Weight to Overweight and set a new price target of $42.00
- PRQIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and BiopharmaPlanned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
- PRQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakTwo custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts
- PRQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsNew AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man
- PRQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIACollaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insigh
- PRQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingCo-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been app
- PRQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB TestingAmbition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care QIAGEN and Diasorin driving LIAISON adoption with LIAISON QuantiFERON-TB Gold Plus II, designed to deliver significant throughput and workflow benefits in the U.S. and Europe
- PRQIAGEN Reports Full Results for Q1 2026Q1 2026 results in line with pre-announcement: Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook Adjusted operating income margin at 27.4%, as ongoing high level of profitability absorbs Parse investments and headwinds from tariffs and currency movements Updated full-year 2026 outlook reconfirmed: Net sales growth of about 1-2% CER and adj. diluted EPS of at least $2.
- ANALYSTQiagen upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Qiagen from Neutral to Outperform and set a new price target of $43.00
- PRQIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlookSample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. For Q1 2026, preliminary net sales were $492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER g
- PRQIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis QIAsymphony Connect will serve as a foundation for lab workflows, enabling standardized nucleic acid extraction for clinical and translational research Introduction of the QIAGEN Discovery Platform, an AI-grounding solution to power downstream AI applications and support drug discovery for research purposes QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrat
- PRQIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx PanelQIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making Launch marks QIAGEN's expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The lau
- ANALYSTQiagen downgraded by Barclays with a new price targetBarclays downgraded Qiagen from Overweight to Equal Weight and set a new price target of $44.00
- PRQiagen Announces Form 20-F Annual Report Filing for 2025 ResultsQIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2025 Annual Report please use our contact form or send an email to ir@qiagen.com. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and a
- SECSEC Form 20-F filed by Qiagen N.V.20-F - QIAGEN N.V. (0001015820) (Filer)
- SECSEC Form IRANNOTICE filed by Qiagen N.V.IRANNOTICE - QIAGEN N.V. (0001015820) (Filer)
- PRQIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB PreventionNew study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-ri
- ANALYSTQiagen upgraded by Deutsche Bank with a new price targetDeutsche Bank upgraded Qiagen from Hold to Buy and set a new price target of $54.00
- PRQIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing SystemFDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months Laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system QIAstat-Dx Rise delivers higher-throughput automation for up to 160 tests per day with minimal hands-on time while supporting urgent sample prioritization QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndrom
QGEN FAQ
8 questionsWhat does Qiagen N.V. do?
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid...Where does QGEN stock trade?
Qiagen N.V. (QGEN) is listed on NYSE.What sector and industry is QGEN in?
Qiagen N.V. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Qiagen N.V. go public?
Qiagen N.V. (QGEN) completed its IPO in 2026.Does QGEN pay a dividend?
QGEN's most recent ex-dividend date was 2026-07-07 with a cash dividend of $0.35 per share. No future ex-date is on file yet.What are analysts saying about QGEN?
Qiagen N.V. has had 8 recent analyst actions on file. The most recent action was from Berenberg: Hold with a $4550.00 price target on 2026-07-14. Recent price targets range from $3860.00 to $4550.00.What companies are similar to QGEN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), ILMN (Illumina Inc.), BIO (Bio-Rad Laboratories Inc.). Compare QGEN side-by-side with any of them on Quantisnow.How can I track QGEN on Quantisnow?
Quantisnow aggregates Qiagen N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QGEN to receive live email and push alerts on every new disclosure.